Cyrus Poonawalla, the Managing Director of the Serum Institute of India (SII), made an announcement on Wednesday regarding the company's upcoming launch of a malaria vaccine. Poonawalla expressed that this vaccine would not only benefit India but also aid in addressing malaria cases in Africa.
In his statement, Poonawalla highlighted that following the success of Covishield, SII is poised to introduce a groundbreaking malaria vaccine, marking a significant milestone in global healthcare. He emphasised the prevalence of malaria infections in the remote regions of India and the urgent need for effective preventive measures.
Also read: 9 Versatile Health benefits of Macadamia Nuts
Dengue is a significant public health concern in India. It is a mosquito-borne viral disease caused by the dengue virus, which is transmitted to humans through the bites of infected female Aedes mosquitoes, primarily Aedes aegypti. Whereas, malaria is a life-threatening vector-borne infectious disease caused by the Plasmodium parasite and transmitted to humans through the bite of infected female Anopheles mosquitoes.
Furthermore, Poonawalla revealed that SII is actively working on a vaccine for dengue, another mosquito-borne viral infection. He projected that a dengue vaccine would be available within a year, underscoring the company's commitment to combat vector-borne diseases.
